Create Custom Knock-In Mouse Models

Gene Mutation or Replacement

When your study calls for generation of a knock-in mouse, Taconic Biosciences’s experts are here to help, whether you’re inserting a reporter to track gene expression, identifying transcriptional regulation elements, or adding in new functionality like human-specific genes or tools like Cre recombinase. At any stage, from concept to implementation, we’re ready to help you create the right knock-in mouse for your study.
The similarities of the human and mouse genomes are extensive, but drug administration in mice does not always translate to humans; false positives and negatives are common occurrences. Exchanging murine genes with their human orthologs can transform mice into more human-like models of human physiology and disease.
You can rely on Taconic Biosciences' genetic mouse models to consistently and faithfully express human transgenes. Use genetically models to gain insights into pathogenic mechanisms, predict human metabolism of therapeutic compounds, and streamline therapeutic discovery and development.
Constitutive Knock-In:
Constitutive Knock-In Allele

Conditional Knock-In:
Conditional Knock-In Allele

Human Gene Knock-In with Optional Conditional KO:
Humanized Conditional Allele

Constitutive Knock-In with Optional Conditional KO:
Constitutive Optional Conditional Allele

Give us a gene accession number and we’ll do the rest. Taconic's highly experienced design team will carefully evaluate your project and suggest the most appropriate strategy for humanizing your mouse.

Once you approve the design, we'll make the model:

  • Your targeting vector will be constructed with cloning technology that minimizes the introduction of unwanted mutations.
  • Your vector will be fully sequenced and electroporated into our highly germline competent C57BL/6NTac ES cells or one of a wide array of validated ES cell lines.
  • Clones thoroughly validated by Southern Blot will be injected into mouse blastocysts and transferred into pseudopregnant female mice.
  • The resulting chimeras will be bred to our highly efficient deleter mice to remove selection markers and achieve germline transmission in a single step. If necessary we can remove the selection marker in vitro already in the ES cells.

Strict quality control
We have rigorous processes in place to ensure you receive the model you requested:

  1. Validate all ES cells
  2. Perform health and genetic testing of all ES cell lines
  3. Generate Flp- and Cre-deleted lines.

In addition, you can get validated genotyping protocols for your mice.

Fast timelines
Taconic understands how valuable your time is and offers the fastest delivery times in the industry.

One point of contact
Get regular updates from your expert project manager—dedicated to your project—so you'll always know the status of your model generation.

Detailed milestone reports
Access detailed reports online on the progress of your project at the end of each milestone:

  • Targeting vector construction
  • Targeted and validated ES cells
  • Mouse model completion

Detailed Milestone Reports
Packages include:

  • Documentation and verification of PCR-based genotype protocol
  • Coordinated transfer of donor males to Taconic's breeding facility in Germantown, NY.
  • Confirmation of genotype of donor males by PCR-based genotyping.
  • Rapid Expansion using C57BL/6NTac donor females.
  • Holding of excess donor males until offspring from rapid expansion are weaned.
  • Comprehensive health testing with breeding while waiting for results of IHMS™-52 health testing.
  • PCR based genotyping of derived offspring.
Package includes:

  • Barrier breeding of derived offspring in a heterozygous x heterozygous mating format.
  • PCR based genotyping of offspring from heterozygous x heterozygous mating.
  • Initial cohort of animals ready for shipment from 5 weeks of age on.
  • Large Cohort 8-10/sex/genotype.
  • Small Cohort 4-6/sex/genotype.
  • Genotypes include homozygous, heterozygous, and wild type.

Notes:

  • Package ends when initial cohort is ready for shipping. Post Package breeding and fees will be based on your breeding plan.
  • Shipping charges from Taconic to customer are not included in package.
  • Package assumes receipt of 4 donor males from Taconic, additional services will be charged at catalog prices.
  • Pricing assumes genetic modification is not sex linked, Mendelian ratios will be obtained, 80% of female breeders will deliver live pups that survive until weaning, and an average litter size of 5 pups. Additional charges may apply if these conditions are not met.
Package includes:

  • Barrier breeding of derived offspring heterozygous for the conditional allele with your Cre* line of interest.
  • PCR-based genotyping of offspring from above mating.
  • Barrier breeding of double heterozygous mice to generate appropriate experimental and control groups.
  • PCR-based genotyping of offspring from the above mating.
  • Initial cohort of animals ready for shipment at the beginning at 5 weeks of age.
  • Large package 8-10/sex/genotype.
  • Small package 4-6/sex/genotype.
  • Genotypes include homozygous for Cre-derived null deletion and wild type.

Notes:

  • Package ends when initial cohort is ready for shipping. Post package breeding and fees will be based on your breeding plan.
  • Shipping charges from Taconic to customer are not included in package
  • Package assumes receipt of 4 donor males from Taconic. Additional services will be charged at catalog prices.
  • Package assumes use of Taconic ubiquitous general Cre Deleter mice (12524-T) will be used for crossbreeding. Additional fees may apply if different Cre mouse is used.
  • Pricing assumes genetic modification is not sex linked, Mendelian ratios will be obtained, 80% of female breeders will deliver live pups that survive until weaning, and an average litter size of 5 pups. Additional charges may apply if these conditions are not met.
Edwards JP, Thornton AM, Shevach EM. (2014) Release of active TGF-β1 from the latent TGF-β1/GARP complex on T regulatory cells is mediated by integrin β8. J Immunol. 193(6):2843-9.

Guo T, Marmol P, Moliner A, Björnholm M, Zhang C, Shokat KM, Ibanez CF. (2014) Adipocyte ALK7 links nutrient overload to catecholamine resistance in obesity. Elife. 3:e03245.

Hasegawa M, Kapelyukh Y, Tahara H, Seibler J, Rode A, Krueger S, Lee DN, Wolf CR, Scheer N. (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol. 80(3):518-28.

Jun LS, Showalter AD, Ali N, Dai F, Ma W, Coskun T, Ficorilli JV, Wheeler MB, Michael MD, Sloop KW. (2014) A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor. PLoS One. 9(4):e93746.

Kawano S. (1988) Carcinoembryonic antigen in tumor tissue and urine in cases with primary bladder cancer--a study by immunogold-silver staining and radioimmunoassay. Nihon Hinyokika Gakkai Zasshi. 79(3):469-74. [Article in Japanese].

McMillan SJ, Richards HE, Crocker PR. (2014) Siglec-F-dependent negative regulation of allergen-induced eosinophilia depends critically on the experimental model. Immunol Lett. 160(1):11-6.

Ross J, Plummer SM, Rode A, Scheer N, Bower CC, Vogel O, Henderson CJ, Wolf CR, Elcombe CR. (2010) Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol Sci. 116(2):452-66.

Scheer N, Wolf CR. (2014) Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica. 44(2):96-108.

Scheer N, Snaith M, Wolf CR, Seibler J. (2013) Generation and utility of genetically humanized mouse models. Drug Discov Today. 18(23-24):1200-11.

Scheer N, Balimane P, Hayward MD, Buechel S, Kauselmann G, Wolf CR.(2012) Generation and characterization of a novel multidrug resistance protein 2 humanized mouse line. Drug Metab Dispos. 40(11):2212-8.

Scheer N, Kapelyukh Y, Chatham L, Rode A, Buechel S, Wolf CR. (2012) Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol. 82(6):1022-9.

Scheer N, Kapelyukh Y, McEwan J, Beuger V, Stanley LA, Rode A, Wolf CR. (2012) Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol. 81(1):63-72.

Scheer N, Ross J, Kapelyukh Y, Rode A, Wolf CR. (2010) In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. Drug Metab Dispos. 38(7):1046-53.

Scheer N, Ross J, Rode A, Zevnik B, Niehaves S, Faust N, Wolf CR. (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest. 118(9):3228-39.

Xu D, Rowland SE, Clark P, Giroux A, Cĉté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D. (2008) MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 326(3):754-63.

Zhang J, Clark K, Lawrence T, Peggie MW, Cohen P. (2014) An unexpected twist to the activation of IKKβ: TAK1 primes IKKβ for activation by autophosphorylation. Biochem J. 461(3):531-7.

Zevnik B, Uyttersprot NC, Perez AV, Bothe GW, Kern H, Kauselmann G. (2014) C57BL/6N albino/agouti mutant mice as embryo donors for efficient germline transmission of C57BL/6 ES cells. PLoS One. 9(3):e90570.